ATAI News and Press, ATAI Life Sciences N.V.

Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...

Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...

2024-07-11 07:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That’s because the world of drug developmen...

2024-07-08 07:45:54 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly us...

2024-07-06 07:21:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning s...

2024-07-03 09:48:30 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelics could be a game-changer in treating mental health issues. All of which could help create big opportunities for top psychedelic stocks. According to the American Psychologi...

NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s manage...

--News Direct-- Atai Life Sciences co-founder and co-CEO Florian Brand discussed initial results from Beckley Psytech’s phase 1 trial of its patent-protected psilocin ELE-101 in patients with major depressive disorder. Brand explained that ELE-101 is an intravenous (IV) formula...

About a week ago, an advisory committee to the U.S. Food and Drug Administration (FDA) rejected evidence supporting the approval of MDMA as an alternative treatment for post-traumatic stress disorder (PTSD). This is a deflating moment for many in psychedelic research who have, for years, conduc...

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours. The Phase 2a part of the study will evaluate the safety, tolerability, subj...